Search results
Showing 16 to 30 of 59 results for botulinum a toxin
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
Question Method of botulinum toxin type A injection in treating focal spasticity:- Is guided botulinum...
Botulinum toxin type A for preventing episodic migraine ID 6450
Awaiting development [GID-TA11505] Expected publication date: TBC
What is the long-term effectiveness of bladder wall injection with botulinum toxin type A for overactive bladder in women?...
CG148/5 Question What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and...
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.
Cerebral palsy in under 25s: assessment and management (NG62)
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
Social anxiety disorder: recognition, assessment and treatment (CG159)
This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.
Occipital nerve stimulation for intractable chronic migraine (IPG452)
Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.
View recommendations for IPG452Show all sections
Sections for IPG452
Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve to treat cluster headache and migraine in adults. This involves using a small handheld device to stimulate a nerve in the neck.
Transcranial magnetic stimulation for treating and preventing migraine (IPG477)
Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.